Overview

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Status:
Completed

Trial end date:
2019-07-31

Target enrollment:

Participant gender:

Summary

The overall goal of this imaging trial is to evaluate [18F]PI-2620, a tau targeted positron emission computed tomography radioligand, in individuals with tauopathies and healthy volunteers (HV).

Phase:

Early Phase 1

Details

Lead Sponsor:

Asan Medical Center

Collaborator:

Korea Health Industry Development Institute